Breye Therapeutics
Breye Therapeutics develops oral medicines for retinal diseases.
€67.5MSeries A
ParticipantActivity from announced rounds
Breye Therapeutics develops oral medicines for retinal diseases.
Develops AI-powered imaging tools for stroke and lung fibrosis
Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease